Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States


   All

Last Update: 02-09-2013  
Related category(ies):
Health & life sciences  |  Success stories  |  Special Collections

 

Countries involved in the project described in the article:
Austria  |  Denmark  |  France  |  Haiti  |  Hungary  |  Spain  |  Switzerland  |  United Kingdom
Add to PDF "basket"

HIV vaccine on trial

A team of French scientists has started clinical trials on humans for a potential HIV/AIDS vaccine.

Video in QuickTime format:  ar  de  en  es  fa  fr  it  pt  ru  tr  uk  (12,6 MB)

Chief Scientific Officer at Grenoble-based PX’Therapeutics Nicolas Mouz said: “We’re developping a vaccine against HIV, using a protein of the HIV virus called GP41.

“Why the GP41 protein? Because it’s a key protein in the mechanism of entry of the virus into the cells.

“And it’s a protein which allows the generation of neutralising antibodies, which is the main objective of the vaccine.”

Protein GP41 – remember that name, because that protein could help European researchers overcome one of the world’s most pernicious diseases: HIV/AIDS.

The team at PX’Therapeutics believes GP41’s low level of genetic variability means it could allow them to develop a truly ground-breaking vaccine.

Nicolas Mouz explained: “The idea is to look for an immune response of neutralising antibodies in the mucus. Why in mucus? Because nearly 90% of AIDS cases are due to sexual relations.”

These French researchers are part of a European project that includes clinical trials of their HIV vaccine.

The team is following closely as 50 British volunteers take part in the first round of tests.

PX’Therapeutics’ pharmaceutical director is Lucile Marron Brignone. She said: “After each administration of the product we check if there are any side effects.

“The other objective is to have information about the immunogenicity of the product, that’s to say whether or not it generates an immune response within patients or healthy volunteers.”

The trials have started well – and it is hoped this technology could be part of a truly effective HIV vaccine.

Nicolas Mouz said: “We are probably quite a long way from an AIDS vaccine, but we do believe that this vaccine has real potential, and we could imagine that the future AIDS vaccine will probably be a mix of different subunit vaccines, and that this vaccine subunit could be part of a future vaccine.”

 

Project details

  • Project acronym: EURONEUT-41
  • Participants: France (Coordinator), United Kingdom, Denmark, Germany, Spain, Hungary, Austria, Haiti, Switzerland
  • FP7 Project N° 201038
  • Total costs: €15 922 033
  • EU contribution: €11 966 082
  • Duration: January 2008 - March 2014

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Futuris, the European research programme - on Euronews. The video on this page was prepared in collaboration with Euronews for the Futuris programme.

Project web site

Project information on CORDIS

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center